Though COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024 and so far in 2025, driven by ...

AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to ...

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the ...

AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...

Uniting over 600 industry experts this September 22-25, the 15 th World Clinical Biomarkers & Companion Diagnostics (CDx) ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens ...

OPEN The FTSE 100 was expected to open 6.2 points lower on Friday after closing 0.11% higher in the previous session at 8,811.04.

A fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without ...